New emerging targets in cancer immunotherapy: the role of TIM3

by Friedlaender, Alex, Addeo, Alfredo, Banna, Giuseppe
Published in ESMO Open (2019)

Rethinking the Optimal Duration of Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer Throughout the COVID-19 Pandemic

by Friedlaender, Alex, Kim, Chul, Addeo, Alfredo
Published in Front Oncol (2020)

COVID-19 and lung cancer: risks, mechanisms and treatment interactions

by Addeo, Alfredo, Obeid, Michel, Friedlaender, Alex
Published in J Immunother Cancer (2020)

Tracking the tail

by Friedlaender, Alex, Liu, Stephen V, Addeo, Alfredo
Published in J Immunother Cancer (2020)

ADAURA: Mature Enough for Publication, Not for Prime Time

by Addeo, Alfredo, Banna, Giuseppe Luigi, Friedlaender, Alex
Published in Oncologist (2020)

KRAS G12C Mutations in NSCLC: From Target to Resistance

by Addeo, Alfredo, Banna, Giuseppe Luigi, Friedlaender, Alex
Published in Cancers (Basel) (2021)

The Activity of Immune Checkpoint Inhibition in KRAS Mutated Non-small Cell Lung Cancer: A Single Centre Experience

by TORRALVO, JAVIER, FRIEDLAENDER, ALEX, ACHARD, VERANE, ADDEO, ALFREDO
Published in Cancer Genomics Proteomics (2019)

Influence of Concurrent Mutations on Overall Survival in EGFR-mutated Non-small Cell Lung Cancer

by CHEVALLIER, MATHIEU, TSANTOULIS, PETROS, ADDEO, ALFREDO, FRIEDLAENDER, ALEX
Published in Cancer Genomics Proteomics (2020)

Gender-specific aspects of epidemiology, molecular genetics and outcome: lung cancer

by Mederos, Nuria, Friedlaender, Alex, Peters, Solange, Addeo, Alfredo
Published in ESMO Open (2020)

Oncogenic driver mutations in non-small cell lung cancer: Past, present and future

by Chevallier, Mathieu, Borgeaud, Maxime, Addeo, Alfredo, Friedlaender, Alex
Published in World J Clin Oncol (2021)

Identifying successful biomarkers for patients with non-small-cell lung cancer

by Friedlaender, Alex, Bauml, Joshua, Banna, Giuseppe Luigi, Addeo, Alfredo
Published in Lung Cancer Manag (2019)

How we treat patients with lung cancer during the SARS-CoV-2 pandemic: primum non nocere

by Banna, Giuseppe, Curioni-Fontecedro, Alessandra, Friedlaender, Alex, Addeo, Alfredo
Published in ESMO Open (2020)

Reply to Authors

by Banna, Giuseppe, Curioni-Fontecedro, Alessandra, Friedlaender, Alex, Addeo, Alfredo
Published in ESMO Open (2020)

Vertebral Metastasis Treated by Vertebroplasty, a Cause of Respiratory Failure: Case Report and Literature Review

by Chevallier, Mathieu, Chevallier-Lugon, Chloé, Friedlaender, Alex, Addeo, Alfredo
Published in Case Rep Oncol (2021)

Next Generation Sequencing and Genetic Alterations in Squamous Cell Lung Carcinoma: Where Are We Today?

by Friedlaender, Alex, Banna, Giuseppe, Malapelle, Umberto, Pisapia, Pasquale, Addeo, Alfredo
Published in Front Oncol (2019)

Immune checkpoint inhibitor-induced aseptic meningitis and encephalitis: a case-series and narrative review

by Thouvenin, Laure, Olivier, Timothée, Banna, Giuseppe, Addeo, Alfredo, Friedlaender, Alex
Published in Ther Adv Drug Saf (2021)

The Impact of Variant Allele Frequency in EGFR Mutated NSCLC Patients on Targeted Therapy

by Friedlaender, Alex, Tsantoulis, Petros, Chevallier, Mathieu, De Vito, Claudio, Addeo, Alfredo
Published in Front Oncol (2021)

KRAS as a druggable target in NSCLC: Rising like a phoenix after decades of development failures

by Friedlaender, Alex, Drilon, Alexander, Weiss, Glen J, Banna, Giuseppe L, Addeo, Alfredo
Published in Cancer Treat Rev (2020)

Tissue-Plasma TMB Comparison and Plasma TMB Monitoring in Patients With Metastatic Non-small Cell Lung Cancer Receiving Immune Checkpoint Inhibitors

by Friedlaender, Alex, Nouspikel, Thierry, Christinat, Yann, Ho, Liza, McKee, Thomas, Addeo, Alfredo
Published in Front Oncol (2020)

Targeted Therapies in Early Stage NSCLC: Hype or Hope?

by Friedlaender, Alex, Addeo, Alfredo, Russo, Alessandro, Gregorc, Vanesa, Cortinovis, Diego, Rolfo, Christian D.
Published in Int J Mol Sci (2020)